Report cover image

Global PD-1 and PD-L1 Inhibitors Competitive Landscape Professional Research Report 2025

Publisher DIResearch
Published Jan 23, 2025
Length 170 Pages
SKU # DIR19532688

Description

Global PD-1 and PD-L1 Inhibitors Competitive Landscape Professional Research Report 2025



Research Summary

PD-1 (Programmed Cell Death Protein 1) and PD-L1 (Programmed Cell Death Ligand 1) inhibitors are a class of immunotherapy drugs used in cancer treatment. PD-1 is a protein found on the surface of certain immune cells, while PD-L1 is a protein found on some cancer cells. The interaction between PD-1 and PD-L1 can suppress the immune system＇s ability to recognize and attack cancer cells, allowing cancer to evade the body＇s natural defenses. PD-1 and PD-L1 inhibitors are designed to block this interaction, thereby ＂releasing the brakes＂ on the immune system and allowing it to recognize and attack cancer cells more effectively. These inhibitors have shown remarkable success in treating various types of cancer, improving patient outcomes, and often leading to long-lasting responses. They are part of the broader field of immune checkpoint inhibitors, which are transforming the landscape of cancer therapy by harnessing the body＇s immune system to combat cancer.

According to DIResearch's in-depth investigation and research, the global PD-1 and PD-L1 Inhibitors market size was valued at XX Million USD in 2024 and is projected to reach XX Million USD by 2032, with a CAGR of XX% (2025-2032). Notably, the China market has changed rapidly in the past few years. By 2024, China's market size is expected to be XX Million USD, representing approximately XX% of the global market share. By 2032, it is anticipated to grow further to XX Million USD, contributing XX% to the worldwide market share.

The major global  manufacturers of PD-1 and PD-L1 Inhibitors include Merck, Bristol-Myers Squibb, Pfizer, Sanofi, Regeneron Pharmaceuticals, Roche, AstraZeneca, Hengrui Medicine, Beigene, Innovent Biologics, Junshi Biosciences, Akeso, Alphamab Oncology etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.

This report studies the market size, price trends and future development prospects of PD-1 and PD-L1 Inhibitors. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global PD-1 and PD-L1 Inhibitors market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.

The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the PD-1 and PD-L1 Inhibitors market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of PD-1 and PD-L1 Inhibitors industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.  

The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.

Global Key Manufacturers of PD-1 and PD-L1 Inhibitors Include:

Merck

Bristol-Myers Squibb

Pfizer

Sanofi

Regeneron Pharmaceuticals

Roche

AstraZeneca

Hengrui Medicine

Beigene

Innovent Biologics

Junshi Biosciences

Akeso

Alphamab Oncology

PD-1 and PD-L1 Inhibitors Product Segment Include:

PD-1

PD-L1

PD-1 and PD-L1 Inhibitors Product Application Include:

Metastatic Melanoma

Non-small Cell Lung Cancer (NSCLC)

Renal Cell Carcinoma (RCC)

Others

Chapter Scope

Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends

Chapter 2: Global PD-1 and PD-L1 Inhibitors Industry PESTEL Analysis

Chapter 3: Global PD-1 and PD-L1 Inhibitors Industry Porter’s Five Forces Analysis

Chapter 4: Global PD-1 and PD-L1 Inhibitors Major Regional Market Size (Revenue, Sales, Price) and Forecast Analysis

Chapter 5: Global PD-1 and PD-L1 Inhibitors Market Size and Forecast by Type and Application Analysis

Chapter 6: North America PD-1 and PD-L1 Inhibitors Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 7: Europe PD-1 and PD-L1 Inhibitors Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 8: China PD-1 and PD-L1 Inhibitors Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 9: APAC (Excl. China) PD-1 and PD-L1 Inhibitors Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 10: Latin America PD-1 and PD-L1 Inhibitors Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 11: Middle East and Africa PD-1 and PD-L1 Inhibitors Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 12: Global PD-1 and PD-L1 Inhibitors Competitive Analysis of Key Manufacturers (Sales, Revenue, Market Share, Price, Regional Distribution and Industry Concentration)

Chapter 13: Key Company Profiles (Product Portfolio, Sales, Revenue, Price and Gross Margin)

Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers

Chapter 15: Research Findings and Conclusion

Chapter 16: Methodology and Data Sources

Table of Contents

170 Pages
1 PD-1 and PD-L1 Inhibitors Market Overview
1.1 Product Definition and Statistical Scope
1.2 PD-1 and PD-L1 Inhibitors Product by Type
1.2.1 PD-1
1.2.2 PD-L1
1.3 PD-1 and PD-L1 Inhibitors Product by Application
1.3.1 Metastatic Melanoma
1.3.2 Non-small Cell Lung Cancer (NSCLC)
1.3.3 Renal Cell Carcinoma (RCC)
1.3.4 Others
1.4 Global PD-1 and PD-L1 Inhibitors Market Revenue and Sales Analysis
1.4.1 Global PD-1 and PD-L1 Inhibitors Revenue Market Size Analysis (2020-2032)
1.4.2 Global PD-1 and PD-L1 Inhibitors Sales Market Size Analysis (2020-2032)
1.4.3 Global PD-1 and PD-L1 Inhibitors Market Sales Price Trend Analysis (2020-2032)
1.5 PD-1 and PD-L1 Inhibitors Industry Trends and Innovation
1.5.1 PD-1 and PD-L1 Inhibitors Industry Trends and Innovation
1.5.2 PD-1 and PD-L1 Inhibitors Market Drivers and Challenges
2 PD-1 and PD-L1 Inhibitors Market PESTEL Analysis
2.1 Political Factors Analysis
2.2 Economic Factors Analysis
2.3 Social Factors Analysis
2.4 Technological Factors Analysis
2.5 Environmental Factors Analysis
2.6 Legal Factors Analysis
3 PD-1 and PD-L1 Inhibitors Market Porter's Five Forces Analysis
3.1 Competitive Rivalry
3.2 Threat of New Entrants
3.3 Bargaining Power of Suppliers
3.4 Bargaining Power of Buyers
3.5 Threat of Substitutes
4 Global PD-1 and PD-L1 Inhibitors Market Analysis by Regions
4.1 PD-1 and PD-L1 Inhibitors Overall Market: 2024 VS 2025 VS 2032
4.2 Global PD-1 and PD-L1 Inhibitors Revenue and Forecast Analysis (2020-2032)
4.2.1 Global PD-1 and PD-L1 Inhibitors Revenue and Market Share by Region (2020-2025)
4.2.2 Global PD-1 and PD-L1 Inhibitors Revenue and Market Share Forecast by Region (2026-2032)
4.3 Global PD-1 and PD-L1 Inhibitors Sales and Forecast Analysis (2020-2032)
4.3.1 Global PD-1 and PD-L1 Inhibitors Sales and Market Share by Region (2020-2025)
4.3.2 Global PD-1 and PD-L1 Inhibitors Sales Forecast by Region (2026-2032)
4.4 Global PD-1 and PD-L1 Inhibitors Sales Price Trend Analysis (2020-2032)
5 Global PD-1 and PD-L1 Inhibitors Market Size by Type and Application
5.1 Global PD-1 and PD-L1 Inhibitors Market Size by Type
5.1.1 Global PD-1 and PD-L1 Inhibitors Revenue and Forecast Analysis by Type (2020-2032)
5.1.2 Global PD-1 and PD-L1 Inhibitors Sales and Forecast Analysis by Type (2020-2032)
5.2 Global PD-1 and PD-L1 Inhibitors Market Size by Application
5.2.1 Global PD-1 and PD-L1 Inhibitors Revenue and Forecast Analysis by Application (2020-2032)
5.2.2 Global PD-1 and PD-L1 Inhibitors Sales and Forecast Analysis by Application (2020-2032)
6 North America
6.1 North America PD-1 and PD-L1 Inhibitors Market Size and Growth Rate Analysis (2020-2032)
6.2 North America Key Manufacturers Analysis
6.3 North America PD-1 and PD-L1 Inhibitors Market Size by Type
6.3.1 North America PD-1 and PD-L1 Inhibitors Sales by Type (2020-2032)
6.3.2 North America PD-1 and PD-L1 Inhibitors Revenue by Type (2020-2032)
6.4 North America PD-1 and PD-L1 Inhibitors Market Size by Application
6.4.1 North America PD-1 and PD-L1 Inhibitors Sales by Application (2020-2032)
6.4.2 North America PD-1 and PD-L1 Inhibitors Revenue by Application (2020-2032)
6.5 North America PD-1 and PD-L1 Inhibitors Market Size by Country
6.5.1 US
6.5.2 Canada
7 Europe
7.1 Europe PD-1 and PD-L1 Inhibitors Market Size and Growth Rate Analysis (2020-2032)
7.2 Europe Key Manufacturers Analysis
7.3 Europe PD-1 and PD-L1 Inhibitors Market Size by Type
7.3.1 Europe PD-1 and PD-L1 Inhibitors Sales by Type (2020-2032)
7.3.2 Europe PD-1 and PD-L1 Inhibitors Revenue by Type (2020-2032)
7.4 Europe PD-1 and PD-L1 Inhibitors Market Size by Application
7.4.1 Europe PD-1 and PD-L1 Inhibitors Sales by Application (2020-2032)
7.4.2 Europe PD-1 and PD-L1 Inhibitors Revenue by Application (2020-2032)
7.5 Europe PD-1 and PD-L1 Inhibitors Market Size by Country
7.5.1 Germany
7.5.2 France
7.5.3 United Kingdom
7.5.4 Italy
7.5.5 Spain
7.5.6 Benelux
8 China
8.1 China PD-1 and PD-L1 Inhibitors Market Size and Growth Rate Analysis (2020-2032)
8.2 China Key Manufacturers Analysis
8.3 China PD-1 and PD-L1 Inhibitors Market Size by Type
8.3.1 China PD-1 and PD-L1 Inhibitors Sales by Type (2020-2032)
8.3.2 China PD-1 and PD-L1 Inhibitors Revenue by Type (2020-2032)
8.4 China PD-1 and PD-L1 Inhibitors Market Size by Application
8.4.1 China PD-1 and PD-L1 Inhibitors Sales by Application (2020-2032)
8.4.2 China PD-1 and PD-L1 Inhibitors Revenue by Application (2020-2032)
9 APAC (excl. China)
9.1 APAC (excl. China) PD-1 and PD-L1 Inhibitors Market Size and Growth Rate Analysis (2020-2032)
9.2 APAC (excl. China) Key Manufacturers Analysis
9.3 APAC (excl. China) PD-1 and PD-L1 Inhibitors Market Size by Type
9.3.1 APAC (excl. China) PD-1 and PD-L1 Inhibitors Sales by Type (2020-2032)
9.3.2 APAC (excl. China) PD-1 and PD-L1 Inhibitors Revenue by Type (2020-2032)
9.4 APAC (excl. China) PD-1 and PD-L1 Inhibitors Market Size by Application
9.4.1 APAC (excl. China) PD-1 and PD-L1 Inhibitors Sales by Application (2020-2032)
9.4.2 APAC (excl. China) PD-1 and PD-L1 Inhibitors Revenue by Application (2020-2032)
9.5 APAC (excl. China) PD-1 and PD-L1 Inhibitors Market Size by Country
9.5.1 Japan
9.5.2 South Korea
9.5.3 India
9.5.4 Australia
9.5.5 Southeast Asia
10 Latin America
10.1 Latin America PD-1 and PD-L1 Inhibitors Market Size and Growth Rate Analysis (2020-2032)
10.2 Latin America Key Manufacturers Analysis
10.3 Latin America PD-1 and PD-L1 Inhibitors Market Size by Type
10.3.1 Latin America PD-1 and PD-L1 Inhibitors Sales by Type (2020-2032)
10.3.2 Latin America PD-1 and PD-L1 Inhibitors Revenue by Type (2020-2032)
10.4 Latin America PD-1 and PD-L1 Inhibitors Market Size by Application
10.4.1 Latin America PD-1 and PD-L1 Inhibitors Sales by Application (2020-2032)
10.4.2 Latin America PD-1 and PD-L1 Inhibitors Revenue by Application (2020-2032)
10.5 Latin America PD-1 and PD-L1 Inhibitors Market Size by Country
10.6 Latin America PD-1 and PD-L1 Inhibitors Market Size by Country
10.6.1 Mexico
10.6.2 Brazil
11 Middle East & Africa
11.1 Middle East & Africa PD-1 and PD-L1 Inhibitors Market Size and Growth Rate Analysis (2020-2032)
11.2 Middle East & Africa Key Manufacturers Analysis
11.3 Middle East & Africa PD-1 and PD-L1 Inhibitors Market Size by Type
11.3.1 Middle East & Africa PD-1 and PD-L1 Inhibitors Sales by Type (2020-2032)
11.3.2 Middle East & Africa PD-1 and PD-L1 Inhibitors Revenue by Type (2020-2032)
11.4 Middle East & Africa PD-1 and PD-L1 Inhibitors Market Size by Application
11.4.1 Middle East & Africa PD-1 and PD-L1 Inhibitors Sales by Application (2020-2032)
11.4.2 Middle East & Africa PD-1 and PD-L1 Inhibitors Revenue by Application (2020-2032)
11.5 Middle East PD-1 and PD-L1 Inhibitors Market Size by Country
11.5.1 Saudi Arabia
11.5.2 South Africa
12 Competition by Manufacturers
12.1 Global PD-1 and PD-L1 Inhibitors Market Sales, Revenue and Price by Key Manufacturers (2021-2025)
12.1.1 Global PD-1 and PD-L1 Inhibitors Market Sales by Key Manufacturers (2021-2025)
12.1.2 Global PD-1 and PD-L1 Inhibitors Market Revenue by Key Manufacturers (2021-2025)
12.1.3 Global PD-1 and PD-L1 Inhibitors Average Sales Price by Manufacturers (2021-2025)
12.2 PD-1 and PD-L1 Inhibitors Competitive Landscape Analysis and Market Dynamic
12.2.1 PD-1 and PD-L1 Inhibitors Competitive Landscape Analysis
12.2.2 Global Key Manufacturers Headquarter Location and Key Area Sales
12.2.3 Market Dynamic
13 Key Companies Analysis
13.1 Merck
13.1.1 Merck Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.1.2 Merck PD-1 and PD-L1 Inhibitors Product Portfolio
13.1.3 Merck PD-1 and PD-L1 Inhibitors Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
13.2 Bristol-Myers Squibb
13.2.1 Bristol-Myers Squibb Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.2.2 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Product Portfolio
13.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
13.3 Pfizer
13.3.1 Pfizer Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.3.2 Pfizer PD-1 and PD-L1 Inhibitors Product Portfolio
13.3.3 Pfizer PD-1 and PD-L1 Inhibitors Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
13.4 Sanofi
13.4.1 Sanofi Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.4.2 Sanofi PD-1 and PD-L1 Inhibitors Product Portfolio
13.4.3 Sanofi PD-1 and PD-L1 Inhibitors Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
13.5 Regeneron Pharmaceuticals
13.5.1 Regeneron Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.5.2 Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitors Product Portfolio
13.5.3 Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitors Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
13.6 Roche
13.6.1 Roche Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.6.2 Roche PD-1 and PD-L1 Inhibitors Product Portfolio
13.6.3 Roche PD-1 and PD-L1 Inhibitors Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
13.7 AstraZeneca
13.7.1 AstraZeneca Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.7.2 AstraZeneca PD-1 and PD-L1 Inhibitors Product Portfolio
13.7.3 AstraZeneca PD-1 and PD-L1 Inhibitors Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
13.8 Hengrui Medicine
13.8.1 Hengrui Medicine Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.8.2 Hengrui Medicine PD-1 and PD-L1 Inhibitors Product Portfolio
13.8.3 Hengrui Medicine PD-1 and PD-L1 Inhibitors Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
13.9 Beigene
13.9.1 Beigene Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.9.2 Beigene PD-1 and PD-L1 Inhibitors Product Portfolio
13.9.3 Beigene PD-1 and PD-L1 Inhibitors Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
13.10 Innovent Biologics
13.10.1 Innovent Biologics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.10.2 Innovent Biologics PD-1 and PD-L1 Inhibitors Product Portfolio
13.10.3 Innovent Biologics PD-1 and PD-L1 Inhibitors Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
13.11 Junshi Biosciences
13.11.1 Junshi Biosciences Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.11.2 Junshi Biosciences PD-1 and PD-L1 Inhibitors Product Portfolio
13.11.3 Junshi Biosciences PD-1 and PD-L1 Inhibitors Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
13.12 Akeso
13.12.1 Akeso Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.12.2 Akeso PD-1 and PD-L1 Inhibitors Product Portfolio
13.12.3 Akeso PD-1 and PD-L1 Inhibitors Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
13.13 Alphamab Oncology
13.13.1 Alphamab Oncology Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.13.2 Alphamab Oncology PD-1 and PD-L1 Inhibitors Product Portfolio
13.13.3 Alphamab Oncology PD-1 and PD-L1 Inhibitors Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
14 Industry Chain Analysis
14.1 PD-1 and PD-L1 Inhibitors Industry Chain Analysis
14.2 PD-1 and PD-L1 Inhibitors Industry Raw Material and Suppliers Analysis
14.2.1 PD-1 and PD-L1 Inhibitors Key Raw Material Supply Analysis
14.2.2 Raw Material Suppliers and Contact Information
14.3 PD-1 and PD-L1 Inhibitors Typical Downstream Customers
14.4 PD-1 and PD-L1 Inhibitors Sales Channel Analysis
15 Research Findings and Conclusion
16 Methodology and Data Source
16.1 Methodology/Research Approach
16.2 Research Scope
16.3 Benchmarks and Assumptions
16.4 Date Source
16.4.1 Primary Sources
16.4.2 Secondary Sources
16.5 Data Cross Validation
16.6 Disclaimer

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us